Stockreport

ChromaDex to Launch Niagen+, the First-Of-Its-Kind Pharmaceutical-Grade Intravenous and Injectable Niagen® (Patented Nicotinamide Riboside Chloride or NRC) [Yahoo! Finance]

ChromaDex Corporation  (CDXC) 
NASDAQ:AMEX Investor Relations: investors.chromadex.com
PDF blood NAD+ levels peaking sooner and higher three hours post-infusion as compared to NAD+ IV. The U.S. FDA authorized nicotinamide riboside chloride (NRC) for compound [Read more]